CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: December 24, 2020
Result type: Reports
Project Number: SR0671-000
Product Line: Reimbursement Review

Generic Name: risperidone

Brand Name: Perseris

Manufacturer: HLS Therapeutics Inc.

Therapeutic Area: Schizophrenia, adults

Indications: ​Treatment of schizophrenia in adults.

Manufacturer Requested Reimbursement Criteria1: ​Treatment of schizophrenia in adults.

Submission Type: Initial

Project Status: Pending

Call for patient/clinician input open: December 24, 2020

Call for patient/clinician input closed: February 22, 2021

Anticipated Date: January 29, 2021

Fee Schedule: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Submit Feedback